Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD21 trial of BrECADD versus escalated BEACOPP in advanced classical Hodgkin lymphoma
NL-OMON60812Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by University of Cologne. Primary endpoints: Treatment-related morbidity, Progression-free survival and 1 more. Started Dec 2017; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON60812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60812.